Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
Status:
Withdrawn
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Stereotactic
radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to
normal tissue. Erlotinib may make tumor cells more sensitive to radiation therapy. Giving
erlotinib together with stereotactic radiosurgery may kill more tumor cells.
PURPOSE: This phase I clinical trial is studying the side effects of erlotinib when given
together with stereotactic radiosurgery and to see how well it works in treating patients
with non-small cell lung cancer with brain metastases.